Fate Therapeutics Q3 cash $803.6M; FT596/FT516 show 71% and 73% ORR in lymphoma Ph1

FATE THERAPEUTICS INC

2022-Q3 EPS reported -$1.52 revenue$38,777,000

Cash, equivalents and investments $803.6M at Sept 30, 2021; revenue $14.2M from collaborations.
FT596 in r/r BCL: 71% ORR, 50% CR in single-dose cohorts; no ICANS or GVHD, two low-grade CRS events.
FT516 in r/r BCL: 73% ORR, 55% CR in multi-dose cohorts; 63% responders ongoing at median 5.2 months.
FT819 (iPSC-derived CAR T) first patients dosed; FT576 Ph1 enrollment initiated for multiple myeloma.
R&D expenses $53.1M, G&A $15.7M; shares outstanding 95.4M common, 2.8M preferred (convertible 5:1).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.